EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review

Muhammad Atif Khan, Faiza Humayun Khan, Abat Khan, Aneela Majeed, Chelsea Gorsline, Nausheen Ahmed

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.08.014 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Muhammad Atif Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Collaborative Opportunities f…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Cytomegalovirus, Immunotherapy, Adoptive, Virus Activation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Cytomegalovirus (CMV) reactivation is a common complication in immunocompromised patients, but poorly defined in those undergoing chimeric antigen receptor T-cell (CAR-T) therapy. This systematic review investigates the predictors and outcomes of CMV reactivation in CAR-T recipients, focusing on survival, relapses, and nonrelapse mortality (NRM). METHODS: A systematic review was conducted following PRISMA 2020 guidelines to compare outcomes between CMV reactivation (R) and nonreactivation (NR) groups. A comprehensive search of PUBMED, EMBASE, and CENTRAL identified 172 studies, of which 4 met the inclusion criteria. Data was synthesized using descriptive statistical analysis to report frequencies and percentages. RESULTS: Among 462 CAR-T recipients, 114 (24.7%) experienced CMV reactivation, with a median onset of 20 days and 1.73% developing end-organ disease. Reactivation was more common among those receiving BCMA-targeted CAR-T (7% vs. 2.9%) and with prior allo-HSCT (35% vs. 7%). Severe CRS (11.4% vs. 8.6%) and ICANS (37.7% vs. 26.7%) were also more frequent in the reactivation group. Use of immunosuppressive therapy, including steroids (56% vs. 42.8%) and tocilizumab-anakinra (12% vs. 5%), was higher. Studies showed increased 1-year mortality and relapse in the reactivation group, with CMV reactivation independently predicting mortality (HR 2.3, 95% CI: 1.2-4.5, P = .02). CONCLUSION: CMV reactivation is a serious complication in CAR-T therapy, associated with higher mortality, relapse, and NRM. Key risk factors include BCMA-targeted CAR-T, prior allo-HSCT, and severe CRS/ICANS. Targeted monitoring and prophylactic strategies are crucial to improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsCytomegalovirusImmunotherapy, AdoptiveVirus ActivationReceptors, Chimeric AntigenHumansPrognosis

Stichwörter der Autor:innen

CART-TCMV infectionMortalityRelapseRisk factors

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Collaborative Opportunities for Research, Training, And Excellence in Innovation (CORTEX), Kansas C…
  • Montefiore St. Luke's Cornwall, Newburgh, NY.
  • Memorial Cancer Institute, Pembroke Pines, FL.
  • Cleveland Clinic, Cleveland, OH.
  • Department of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.

Zitieren

APA

Khan, M. A., Khan, F. H., Khan, A., Majeed, A., Gorsline, C., & Ahmed, N. (2025). Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.014

Vancouver

Khan MA, Khan FH, Khan A, Majeed A, Gorsline C, Ahmed N. Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.08.014

BibTeX
@article{Khan2025,
  author = {Khan, Muhammad Atif and Khan, Faiza Humayun and Khan, Abat and Majeed, Aneela and Gorsline, Chelsea and Ahmed, Nausheen},
  title = {Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.08.014}
}
Kostenlos starten →